After receiving some unfavorable clinical trial results, a global pharmaceutical company decided to abandon launching a product in its development pipeline that had been expected to achieve “blockbuster” status. After the decision was made, the company’s stock price fell, and the firm was accused of concealing information about the product.
Challenge: CRA assembled a team with expertise in financial markets, economics, and the pharmaceuticals industry to understand the causes of the security price changes. We complemented our econometric analysis of the client’s stock price with an in-depth analysis of the product’s market value for its different potential indications.
Solution: CRA was successful in explaining to the court that the alleged concealment of information was an unlikely explanation for the drop in the securities price alleged by plaintiffs.
Cécile Matthews quoted in Pink Sheet article following study on non-oncology orphan drug pricing in France
Following a recent study on non-oncology orphan drug pricing in France, CRA’s Cécile Matthews was interviewed by reporter Francesca Bruce. The interview was...